Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Current Value
$0.801 Year Return
Current Value
$0.801 Year Return
Market Cap
$228.91M
P/E Ratio
-1.45
1Y Stock Return
-28.00%
1Y Revenue Growth
-41.38%
Dividend Yield
0.00%
Price to Book
4.2
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...
Yahoo
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2024 financial results and business updates.
Finnhub
Precigen Reports Third Quarter 2024 Financial Results and Business Updates - Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path...
Yahoo
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Tuesday, November 19, 2024 from 10:55 to 11:25 AM ET at the Stifel 2024 Healthcare Conference taking place November 18 to 19, 2024 in New York.
Yahoo
Over the last 7 days, the United States market has dropped by 1.0%, yet it has seen a substantial rise of 38% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these promising earnings projections.
SeekingAlpha
During the third quarter of 2024, the Patient Opportunity Equity representative account generated a total return of 5.58% net of fees.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRSP | 55.51% | $4.01B | -30.49% | 0.00% |
NTLA | 52.65% | $1.44B | -50.35% | 0.00% |
BEAM | 52.51% | $2.09B | -9.52% | 0.00% |
RCKT | 51.61% | $1.20B | -39.83% | 0.00% |
OPEN | 50.29% | $1.14B | -31.62% | 0.00% |
ARWR | 49.64% | $2.31B | -34.44% | 0.00% |
DNLI | 49.43% | $3.50B | +33.66% | 0.00% |
IDYA | 49.13% | $2.24B | -15.21% | 0.00% |
BCRX | 48.33% | $1.49B | +41.37% | 0.00% |
PLRX | 48.13% | $778.32M | -9.55% | 0.00% |
RXRX | 47.91% | $1.80B | -4.13% | 0.00% |
CNDT | 47.79% | $569.21M | +20.27% | 0.00% |
ALEC | 46.63% | $377.04M | -19.46% | 0.00% |
MNKD | 46.56% | $1.89B | +84.91% | 0.00% |
PRTA | 45.91% | $756.01M | -56.52% | 0.00% |
CLFD | 45.15% | $398.66M | +4.48% | 0.00% |
FATE | 45.06% | $248.29M | -11.02% | 0.00% |
ALLO | 44.93% | $444.50M | -24.82% | 0.00% |
TWST | 44.74% | $2.42B | +74.27% | 0.00% |
CRNX | 44.46% | $5.12B | +84.27% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PRPO | -15.12% | $9.10M | -13.65% | 0.00% |
LMT | -13.47% | $126.40B | +18.99% | 2.36% |
MCK | -13.16% | $78.15B | +35.51% | 0.42% |
CYD | -12.76% | $364.46M | -2.94% | 4.26% |
STG | -11.99% | $35.67M | +7.92% | 0.00% |
MSDL | -11.36% | $1.83B | +0.66% | 7.26% |
NOC | -11.25% | $71.54B | +4.23% | 1.60% |
PGR | -8.16% | $149.10B | +57.29% | 0.45% |
HUSA | -8.08% | $16.69M | -11.56% | 0.00% |
PULM | -7.81% | $19.83M | +202.98% | 0.00% |
AMED | -7.56% | $2.95B | -3.95% | 0.00% |
CHKP | -7.36% | $19.20B | +20.74% | 0.00% |
FTNT | -7.13% | $69.59B | +72.67% | 0.00% |
OXBR | -6.18% | $19.05M | +178.18% | 0.00% |
CBOE | -6.03% | $21.46B | +15.84% | 1.11% |
TCTM | -5.96% | $8.10M | -42.99% | 0.00% |
ACGL | -5.93% | $36.00B | +16.84% | 0.00% |
CME | -5.45% | $82.76B | +9.21% | 1.98% |
COR | -5.37% | $47.48B | +21.20% | 0.86% |
QTTB | -5.03% | $354.34M | +188.64% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CAH | 0.03% | $28.64B | +12.14% | 1.70% |
CYCN | 0.13% | $4.77M | -16.19% | 0.00% |
FATBB | -0.22% | $81.94M | -12.91% | 11.69% |
IMO | -0.25% | $39.72B | +31.84% | 2.23% |
AMBC | 0.25% | $584.50M | -17.09% | 0.00% |
RSG | 0.29% | $66.05B | +31.79% | 1.04% |
VIST | 0.39% | $4.75B | +67.10% | 0.00% |
ARLP | 0.43% | $3.54B | +26.77% | 10.11% |
RGA | 0.46% | $14.97B | +41.90% | 1.52% |
EQNR | 0.47% | $64.72B | -22.63% | 5.56% |
GIS | 0.55% | $34.85B | -2.91% | 3.78% |
LNG | -0.57% | $49.37B | +24.99% | 0.82% |
UUU | 0.57% | $4.97M | -41.89% | 0.00% |
GL | -0.69% | $9.18B | -8.60% | 0.86% |
JNPR | 0.71% | $11.61B | +30.55% | 2.49% |
PANW | 0.71% | $126.99B | +46.98% | 0.00% |
MMC | -0.75% | $108.41B | +10.89% | 1.37% |
DHT | 0.77% | $1.72B | +5.04% | 9.18% |
STNG | 0.90% | $2.96B | +0.87% | 2.75% |
ALTO | -0.92% | $106.54M | -39.83% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -43.56% | $388.04M | 1.43% |
VIXY | -26.17% | $195.31M | 0.85% |
USDU | -19.92% | $201.97M | 0.5% |
UUP | -18.10% | $309.25M | 0.77% |
COMT | -17.22% | $829.06M | 0.48% |
KMLM | -16.68% | $353.87M | 0.9% |
TAIL | -15.39% | $67.98M | 0.59% |
GSG | -14.86% | $914.42M | 0.75% |
EQLS | -14.72% | $76.08M | 1% |
PDBC | -13.04% | $4.40B | 0.59% |
DBC | -11.74% | $1.39B | 0.87% |
CTA | -11.40% | $350.27M | 0.78% |
USCI | -11.18% | $185.47M | 1.07% |
DBO | -10.80% | $217.57M | 0.77% |
DBE | -10.77% | $50.13M | 0.77% |
WEAT | -10.63% | $120.27M | 0.28% |
DBA | -10.62% | $755.88M | 0.93% |
CORN | -9.15% | $61.12M | 0.2% |
KCCA | -6.29% | $220.51M | 0.87% |
FTGC | -4.85% | $2.17B | 1.02% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ULST | 0.11% | $535.47M | 0.2% |
XBIL | -0.71% | $637.70M | 0.15% |
TBIL | -0.75% | $4.38B | 0.15% |
CCOR | -0.75% | $109.04M | 1.18% |
GCC | -0.79% | $133.23M | 0.55% |
DBMF | 0.80% | $1.02B | 0.85% |
IBHD | -0.88% | $327.80M | 0.35% |
MINT | -0.93% | $11.62B | 0.35% |
TPMN | -1.01% | $40.60M | 0.65% |
CMDY | -1.25% | $279.14M | 0.28% |
XHLF | 1.63% | $874.27M | 0.03% |
CSHI | 1.75% | $482.85M | 0.38% |
FLRN | 1.79% | $2.33B | 0.15% |
BILZ | -1.91% | $563.02M | 0.14% |
BSCO | 2.18% | $2.35B | 0.1% |
BCD | -2.19% | $245.02M | 0.3% |
CANE | 2.26% | $17.72M | 0.29% |
UNG | 2.48% | $908.80M | 1.06% |
CLOI | -2.56% | $715.40M | 0.4% |
HIGH | -2.61% | $302.78M | 0.51% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 68.24% | $6.58B | 0.35% |
IBB | 65.56% | $6.66B | 0.45% |
GNOM | 63.12% | $70.59M | 0.5% |
IWC | 63.07% | $933.99M | 0.6% |
PBE | 62.75% | $258.53M | 0.58% |
ARKG | 62.73% | $1.13B | 0.75% |
PTH | 61.64% | $143.31M | 0.6% |
IWO | 60.44% | $12.56B | 0.24% |
VTWO | 60.20% | $12.38B | 0.1% |
IWM | 60.14% | $75.73B | 0.19% |
KOMP | 59.07% | $2.09B | 0.2% |
ISCG | 59.02% | $640.00M | 0.06% |
FBT | 58.78% | $1.11B | 0.56% |
ESML | 58.63% | $1.90B | 0.17% |
SMMD | 58.50% | $1.24B | 0.15% |
NUSC | 58.13% | $1.27B | 0.31% |
PRFZ | 57.88% | $2.65B | 0.39% |
VXF | 57.77% | $21.54B | 0.06% |
GSSC | 57.74% | $529.86M | 0.2% |
VBK | 57.66% | $19.31B | 0.07% |